-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $41

Benzinga·12/04/2025 13:04:10
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $37 to $41.